Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas

NYU Langone Health72 enrolled

Overview

The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.

The study will employ a survey design that poses physicians with a series of three clinical case vignettes. Each vignette describes an IPMN of varying severity, and the physician will be asked determine whether they would continue or discontinue clinical surveillance in each case. This will be a double-blinded randomized survey study, featuring two arms. Providers will be randomized to either be provided with, or not provided with a risk stratification tool (DART-1) when presented with their clinical case vignettes.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Surgery Risk Assessment

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Membership in either the PACYFIC or PRECEDE consortiums * Physician with expertise in the management of IPMN * Able and willing to complete survey Exclusion Criteria: * Not a member of either the PACYFIC or PRECEDE consortiums * Not a physician with expertise in the management of IPMN

Locations (1)

NYU Langone Health

New York, New York, United States

Outcomes

Primary Outcomes

Number of Decisions to Stop Surveillance Imaging

Time frame: Day 1

Number of Decisions to Continue Surveillance Imaging

Time frame: Day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.